PDCD1 and non-small cell lung carcinoma: Major improvements have been made in NSCLC treatment with the advent of targeted therapies and immune checkpoint inhibitors (ICIs), specifically programmed cell death protein 1 (PD-1) and its ligand (PD-L1) inhibitors [2].